Sameer Shankar

Sameer Shankar

Auto-generated profile, based on publicly available information

Sameer Shankar

Department of Molecular Oncology, University of British Columbia, Vancouver, Canada

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
AJAmy Jamieson
Amy Jamieson
JBJuliana Sobral de Barros
Juliana Sobral de Barros
DCDawn R Cochrane
Dawn R Cochrane
JDJ. Maxwell Douglas
J. Maxwell Douglas
SSSameer Shankar
Sameer Shankar
JMJessica N. McAlpine
Jessica N. McAlpine
Purpose: Shallow whole-genome sequencing (sWGS) can detect copy-number (CN) aberrations. In high-grade serous ovarian cancer (HGSOC) sWGS identified CN signatures such as homologous recombination deficiency (HRD) to direct therapy. We applied sWGS with targeted sequencing to p53abn endometrial cancers to identify additional prognostic stratification and therapeutic opportunities. Experimental Design: sWGS and targeted panel sequencing was performed on formalin-fixed, paraffin-embedded p53abn endometrial cancers. CN alterations, mutational data and CN signatures were derived, and associations to clinicopathologic and outcomes data were assessed. Results: In 187 p53abn endometrial cancers, 5 distinct CN signatures were identified. Signature 5 was associated with BRCA1/2 CN loss with features similar to HGSOC HRD signature. Twenty-two percent of potential HRD cases were identified, 35 patients with signature 5, and 8 patients with BRCA1/2 somatic mutations. Signatures 3 and 4 were associated with a high ploidy state, and CCNE1, ERBB2, and MYC amplifications, with mutations in PIK3CA enriched in signature 3. We observed improved overall survival (OS) for patients with signature 2 and worse OS for signatures 1 and 3. Twenty-eight percent of patients had CCNE1 amplification and this subset was enriched with carcinosarcoma histotype. Thirty-four percent of patients, across all histotypes, had ERBB2 amplification and/or HER2 overexpression on IHC, which was associated with worse outcomes. Mutations in PPP2R1A (29%) and FBXW7 (16%) were among the top 5 most common mutations. Conclusions: sWGS and targeted sequencing identified therapeutic opportunities in 75% of patients with p53abn endometrial cancer. Further research is needed to determine the efficacy of treatments targeting these identified pathways within p53abn endometrial cancers.

3 June 2024
Verified
Other
Open access
AJAmy Jamieson
Amy Jamieson
JBJuliana Sobral de Barros
Juliana Sobral de Barros
DCDawn R Cochrane
Dawn R Cochrane
JDJ. Maxwell Douglas
J. Maxwell Douglas
SSSameer Shankar
Sameer Shankar
JMJessica N. McAlpine
Jessica N. McAlpine
Supplemental figure 10. Kaplan-Meier survival analysis demonstrating improved PFS in p53abn EC patients with endometrioid tumors compared to non-endometrioid tumors (carcinosarcoma, clear cell, serous and other) in the total cohort.

3 June 2024
Verified
Other
Open access
AJAmy Jamieson
Amy Jamieson
JBJuliana Sobral de Barros
Juliana Sobral de Barros
DCDawn R Cochrane
Dawn R Cochrane
JDJ. Maxwell Douglas
J. Maxwell Douglas
SSSameer Shankar
Sameer Shankar
JMJessica N. McAlpine
Jessica N. McAlpine
Supplemental figure 5. Plot summarizing the relationship between BriTROC signature exposures per sample, targeted panel mutations, copy number status, and various clinical correlates

3 June 2024
Verified
Other
Open access
AJAmy Jamieson
Amy Jamieson
JBJuliana Sobral de Barros
Juliana Sobral de Barros
DCDawn R Cochrane
Dawn R Cochrane
JDJ. Maxwell Douglas
J. Maxwell Douglas
SSSameer Shankar
Sameer Shankar
JMJessica N. McAlpine
Jessica N. McAlpine
Supplemental Table 6: Association of Signatures and ERBB2 amplification, p-values using Fisher’s Exact test

3 June 2024
Verified
Other
Open access
AJAmy Jamieson
Amy Jamieson
JBJuliana Sobral de Barros
Juliana Sobral de Barros
DCDawn R Cochrane
Dawn R Cochrane
JDJ. Maxwell Douglas
J. Maxwell Douglas
SSSameer Shankar
Sameer Shankar
JMJessica N. McAlpine
Jessica N. McAlpine
Supplemental Figure 2. Oncoplot of HR associated genes.

3 June 2024
Verified
Other
Open access
AJAmy Jamieson
Amy Jamieson
JBJuliana Sobral de Barros
Juliana Sobral de Barros
DCDawn R Cochrane
Dawn R Cochrane
JDJ. Maxwell Douglas
J. Maxwell Douglas
SSSameer Shankar
Sameer Shankar
JMJessica N. McAlpine
Jessica N. McAlpine
Supplemental figure 11. Kaplan-Meier survival analyses demonstrating no difference in PFS in p53abn EC patients with endometrioid tumors compared to non-endometrioid tumors (carcinosarcoma, clear cell, serous and other) once adjusting for FIGO stage.